600276 Stock Overview
A pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 600276 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Jiangsu Hengrui Medicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥43.55 |
| 52 Week High | CN¥57.53 |
| 52 Week Low | CN¥35.51 |
| Beta | 0.27 |
| 1 Month Change | -11.81% |
| 3 Month Change | -17.16% |
| 1 Year Change | 4.94% |
| 3 Year Change | -12.18% |
| 5 Year Change | -27.86% |
| Change since IPO | 384.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600276 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.1% | -3.0% | -4.0% |
| 1Y | 4.9% | -6.5% | 6.4% |
Return vs Industry: 600276 exceeded the CN Pharmaceuticals industry which returned -6.5% over the past year.
Return vs Market: 600276 underperformed the CN Market which returned 6.4% over the past year.
Price Volatility
| 600276 volatility | |
|---|---|
| 600276 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.1% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 600276 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600276's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 19,611 | Hong Bin Dai | www.hrs.com.cn |
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications.
Jiangsu Hengrui Medicine Co., Ltd. Fundamentals Summary
| 600276 fundamental statistics | |
|---|---|
| Market cap | CN¥276.92b |
| Earnings (TTM) | CN¥5.45b |
| Revenue (TTM) | CN¥26.00b |
50.8x
P/E Ratio10.7x
P/S RatioIs 600276 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600276 income statement (TTM) | |
|---|---|
| Revenue | CN¥26.00b |
| Cost of Revenue | CN¥3.74b |
| Gross Profit | CN¥22.26b |
| Other Expenses | CN¥16.81b |
| Earnings | CN¥5.45b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 31, 2025
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 85.62% |
| Net Profit Margin | 20.96% |
| Debt/Equity Ratio | 0% |
How did 600276 perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield23%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 00:26 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangsu Hengrui Medicine Co., Ltd. is covered by 62 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Changming He | BOCI Research Ltd. |
| Bo Li | BofA Global Research |